{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T10:12:44Z","timestamp":1761991964204,"version":"build-2065373602"},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.clcc.2016.07.019","type":"journal-article","created":{"date-parts":[[2016,9,9]],"date-time":"2016-09-09T16:41:08Z","timestamp":1473439268000},"page":"e15-e22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Regorafenib Versus Trifluridine\/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison"],"prefix":"10.1016","volume":"16","author":[{"given":"Toshiki","family":"Masuishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4684-9734","authenticated-orcid":false,"given":"Hiroya","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Hamauchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azusa","family":"Komori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Kito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiya","family":"Narita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Tsushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Todaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigenori","family":"Kadowaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nozomu","family":"Machida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Fukutomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Onozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Tajika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Muro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keita","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2016.07.019_bib1","unstructured":"Globocan. Estimated cancer incidence, mortality and prevalence worldwide in 2012. Available at: http:\/\/globocan.iarc.fr\/Pages\/fact_sheets_cancer.aspx. Accessed: February 28,\u00a02015."},{"key":"10.1016\/j.clcc.2016.07.019_bib2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","article-title":"FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study","volume":"22","author":"Tournigand","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2016.07.019_bib3","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2016.07.019_bib4","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study","volume":"26","author":"Saltz","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2016.07.019_bib5","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer","volume":"369","author":"Douillard","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2016.07.019_bib6","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","article-title":"Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study","volume":"28","author":"Douillard","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2016.07.019_bib7","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","article-title":"Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status","volume":"29","author":"Van Cutsem","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2016.07.019_bib8","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial","volume":"15","author":"Heinemann","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2016.07.019_bib9","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","article-title":"Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer","volume":"371","author":"Loupakis","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2016.07.019_bib10","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S1470-2045(13)70490-X","article-title":"Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial","volume":"14","author":"Yamada","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2016.07.019_bib11","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity","volume":"129","author":"Wilhelm","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clcc.2016.07.019_bib12","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clcc.2016.07.019_bib13","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0006-2952(00)00253-7","article-title":"Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2'-deoxyribonucleosides","volume":"59","author":"Fukushima","year":"2000","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.clcc.2016.07.019_bib14","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.3892\/or.2014.3487","article-title":"Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models","volume":"32","author":"Tanaka","year":"2014","journal-title":"Oncol Rep"},{"key":"10.1016\/j.clcc.2016.07.019_bib15","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2016.07.019_bib16","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S1470-2045(15)00138-2","article-title":"Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial","volume":"16","author":"Tabernero","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2016.07.019_bib17","doi-asserted-by":"crossref","first-page":"9441","DOI":"10.1200\/JCO.2005.04.4792","article-title":"Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line","volume":"23","author":"Grothey","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2016.07.019_bib18","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.ejca.2015.02.013","article-title":"Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: a phase II trial","volume":"51","author":"Argiles","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clcc.2016.07.019_bib19","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1007\/s10637-015-0271-1","article-title":"Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer","volume":"33","author":"Doi","year":"2015","journal-title":"Invest New Drugs"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002816301463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002816301463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:04:17Z","timestamp":1761519857000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002816301463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S1533002816301463"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2016.07.019","relation":{},"ISSN":["1533-0028"],"issn-type":[{"type":"print","value":"1533-0028"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regorafenib Versus Trifluridine\/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2016.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}